Switch theme
Sign up to access all valuation multiples
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulphate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
2014
50
LTM Revenue $0.8M
LTM EBITDA -$27.2M
$60.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Paradigm Biopharma has a last 12-month revenue of $0.8M and a last 12-month EBITDA of -$27.2M.
In the most recent fiscal year, Paradigm Biopharma achieved revenue of $41K and an EBITDA of -$36.8M.
Paradigm Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Paradigm Biopharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $29K | $41K | XXX | XXX | XXX |
| Gross Profit | -$41K | $18K | XXX | XXX | XXX |
| Gross Margin | -138% | 42% | XXX | XXX | XXX |
| EBITDA | -$32.6M | -$36.8M | XXX | XXX | XXX |
| EBITDA Margin | -110979% | -88894% | XXX | XXX | XXX |
| Net Profit | -$24.7M | -$32.6M | XXX | XXX | XXX |
| Net Margin | -83938% | -78891% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Paradigm Biopharma's stock price is AUD 0 (or $0).
Paradigm Biopharma has current market cap of AUD 121M (or $75.9M), and EV of AUD 96.1M (or $60.4M).
See Paradigm Biopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $60.4M | $75.9M | XXX | XXX | XXX | XXX | $-0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Paradigm Biopharma has market cap of $75.9M and EV of $60.4M.
Paradigm Biopharma's trades at 80.0x LTM EV/Revenue multiple, and -2.2x LTM EBITDA.
Analysts estimate Paradigm Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Paradigm Biopharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $60.4M | XXX | XXX | XXX |
| EV/Revenue | 122.8x | XXX | XXX | XXX |
| EV/EBITDA | -2.0x | XXX | XXX | XXX |
| P/E | -2.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpParadigm Biopharma's NTM/LTM revenue growth is -74%
Paradigm Biopharma's revenue per employee for the last fiscal year averaged $1K, while opex per employee averaged $0.8M for the same period.
Over next 12 months, Paradigm Biopharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Paradigm Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Paradigm Biopharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 41% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -6246% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -6320% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 9447% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 88653% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 99164% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Paradigm Biopharma acquired XXX companies to date.
Last acquisition by Paradigm Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Paradigm Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Paradigm Biopharma founded? | Paradigm Biopharma was founded in 2014. |
| Where is Paradigm Biopharma headquartered? | Paradigm Biopharma is headquartered in Australia. |
| How many employees does Paradigm Biopharma have? | As of today, Paradigm Biopharma has 50 employees. |
| Is Paradigm Biopharma publicy listed? | Yes, Paradigm Biopharma is a public company listed on ASX. |
| What is the stock symbol of Paradigm Biopharma? | Paradigm Biopharma trades under PAR ticker. |
| When did Paradigm Biopharma go public? | Paradigm Biopharma went public in 2015. |
| Who are competitors of Paradigm Biopharma? | Similar companies to Paradigm Biopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Paradigm Biopharma? | Paradigm Biopharma's current market cap is $75.9M |
| What is the current revenue of Paradigm Biopharma? | Paradigm Biopharma's last 12-month revenue is $0.8M. |
| What is the current EBITDA of Paradigm Biopharma? | Paradigm Biopharma's last 12-month EBITDA is -$27.2M. |
| What is the current EV/Revenue multiple of Paradigm Biopharma? | Current revenue multiple of Paradigm Biopharma is 80.0x. |
| What is the current EV/EBITDA multiple of Paradigm Biopharma? | Current EBITDA multiple of Paradigm Biopharma is -2.2x. |
| What is the current revenue growth of Paradigm Biopharma? | Paradigm Biopharma revenue growth between 2023 and 2024 was 41%. |
| Is Paradigm Biopharma profitable? | Yes, Paradigm Biopharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
